|
T9523 |
TGFβRI-IN-3
|
|
TGF-beta/Smad
|
|
TGFβRI-IN-3 inhibits TGFβR1 with an IC 50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 is a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology [1]. |
|
T13137 |
TGFβRI-IN-1
|
|
TGF-beta/Smad
|
|
TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase(IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively ). |
|
T62559 |
TGFβRI-IN-4
|
|
|
|
TGFβRI-IN-4 is a potent, orally active TGFβ receptor type I kinase (TGFβRI) inhibitor that acts on ALK5 (IC50: 44 nM) and NIH3T3 (IC50: 42.5 nM).TGFβRI-IN-4 inhibits tumor growth and tumor weight in a xenograft tumor mod... |
|
T72976 |
TGFβRI-IN-6
|
|
|
|
TGFβRI-IN-6 is a potent TGFβRI inhibitor with an IC50 value of 0.55 nM.TGFβRI-IN-6 has the potential to enhance anti-tumour immunity. |
|
T60931 |
TGFβRI-IN-5
|
|
|
|
TGFβRI-IN-5 (Compound 4b) is a potent TGFβRI inhibitor with an IC50 of 0.08 μM. TGFβRI-IN-5 shows amazing anticancer activity against all the tested cell lines which enhances apoptosis and arrested G2/M phase of cell cyc... |
|
T13139 |
TP-008
|
TGFβRI-IN-2 |
Others
|
|
TGFβRI-IN-2 is a selective, potent and orally active inhibitor of (Activin-Like Kinase 5) ALK 5(pIC50 and pEC50 values of 7.6 and 6.63, respectively). |
|
T5125 |
LY3200882
|
|
TGF-beta/Smad
|
|
LY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). |
|
T12433 |
PF-06952229
|
PF06952229 |
TGF-beta/Smad
|
|
PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer. |
|
T2510 |
Galunisertib
|
LY2157299 |
TGF-beta/Smad
|
|
Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity. |
|
T2109 |
SD-208
|
ALK5 Inhibitor V,SD208 |
TGF-beta/Smad
|
|
SD-208 (ALK5 Inhibitor V), a selective TGF-βRI (ALK5) inhibitor (IC50: 48 nM), is >100-fold selectivity over TGF-βRII. |
|
T6337 |
RepSox
|
ALK5 Inhibitor II,SJN 2511,E-616452 |
ALK
,
TGF-beta/Smad
|
|
RepSox (ALK5 Inhibitor II) is a TGFβR-1/ALK5 inhibitor that selectively inhibits the binding of ATP to ALK5 and the autophosphorylation of ALK5 (IC50=23/4 nM). RepSox induces adipogenesis in MEFs cells. |
|
T9837 |
N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-bromoaniline
|
|
ALK
|
|
Compound 12d is a potent ALK5 inhibitor with an IC50 of 7nM. |
|
T61203 |
ALK5-IN-8
|
|
|
|
ALK5-IN-8 is a highly effective inhibitor of TGFβRI (ALK5). It hinders the phosphorylation of ALK5 on downstream signaling proteins (Smad2 or Smad3) by obstructing the interaction between TGFβRI and ligands. Consequently... |
|
T64051 |
ALK5-IN-9
|
|
|
|
ALK5-IN-9 is a potent, orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation (IC50: 25 nM) and inhibits NIH3T3 cell activity (IC50: 74.6 nM). ALK5-IN-9 has shown research potential in canc... |
|
T2048 |
LY-364947
|
LY 364947,HTS466284 |
MLK
,
Casein Kinase
,
TGF-beta/Smad
,
RIP kinase
|
|
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I. |
|
T35896 |
AZ 12799734
|
AZ12799734 |
ALK
|
|
AZ 12799734 is an orally active, selective and potent dual inhibitor of TGFBR1 and ALK5 with inhibitory effects on BMP and TGFβ for the study of tumours. |
|
T10426 |
AZ12601011
|
|
ALK
|
|
AZ12601011 is a highly potent and selective inhibitor of the TGFBR1 kinase, administered orally. It displays an IC50 of 18 nM and a Kd of 2.9 nM. By selectively targeting ALK4, TGFBR1, and ALK7, AZ12601011 effectively in... |
|
T21295 |
BIX02189
|
BIX 02189 |
ERK
,
MEK
|
|
BIX02189 is a potent and selective inhibitor of MEK5 and ERK5(IC50 : 1.5 nM and 59 nM). |
|
T1744 |
BIX02188
|
|
Apoptosis
,
MEK
|
|
BIX02188 is a selective and potent MEK5 inhibitor that inhibits MEK5-induced apoptosis in cells expressing the oncogenic mutant FLT3-ITD. |
